Transplacental transfer and distribution of pravastatin

American Journal of Obstetrics and Gynecology

Volumn 209, Issue 4, 2013, Pages 373.e1-373.e5

  Nanovskaya, Tatiana N ^a   Patrikeeva, Svetlana L ^a   Paul, Jonathan ^a   Costantine, Maged M ^a   Hankins, Gary D V ^a   Ahmed, Mahmoud S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

pravastatin; preeclampsia; pregnancy; transplacental transfer

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; ESTRONE SULFATE; PACLITAXEL; PHENAZONE; PRAVASTATIN;

APICAL MEMBRANE; BRUSH BORDER; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG UPTAKE; GESTATIONAL AGE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; LIPOPHILICITY; LIQUID SCINTILLATION SPECTROMETRY; LUMINESCENCE; PLACENTA; PLACENTAL TRANSFER; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; SCINTILLATION SPECTROMETRY;

EID: 84884649945     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2013.05.038     Document Type: Conference Paper

References (26)

1. J. Shepherd, S.M. Cobbe, and I. Ford West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia Atheroscler Suppl 5 2004 91 97
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med. 5 339 1998 1349 1357
3. M.M. Costantine, and K. Cleary Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women Obstet Gynecol 121 2 Pt 1 2013 349 353
4. Drugs.com [Internet]. Pravastatin pregnancy and breastfeeding warnings. Drug information online. 1996-2012. Cerner Multum, Inc, version: 12.02. [Revision date: March 21, 2012]. Available at: http://www.drugs.com/pregnancy/ pravastatin.html. Accessed March 1, 2013.
5. T.M. Tanase, and K. Hirose Reproduction studies of pravastatin sodium administered during the period of fetal organogenesis in rats Yakuri Chiryo 15 1987 4883 4894
6. T.M. Tanase, M. Asai, and K. Hirose Reproduction studies of pravastatin sodium administered during the period of fetal organogenesis in rabbits Yakuri Chiryo 15 1987 5005 5011
7. S. Teelucksingh, J. El-Youssef, K. Sohan, and S. Ramsewak Prolonged inadvertent pravastatin use in pregnancy Reprod Toxicol 18 2004 299 300
8. N. Taguchi, E.T. Rubin, and A. Hosokawa Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes Reprod Toxicol 26 2008 175 177
9. A. Hosokawa, B. Bar-Oz, and S. Ito Use of lipid-lowering agents (statins) during pregnancy Can Fam Physician 49 2003 747 749
10. R.J. Edison, and M. Muenke Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins Am J Med Genet 131 2004 287 298
11. T. Hatanaka Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events (review) Clin Pharmacokinet 39 2000 397 412
12. B.A. Hamelin, and J. Turgeon Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors (review) Trends Pharmacol Sci 19 1998 26 37
13. S.M. Singhvi, H.Y. Pan, R.A. Morrison, and D.A. Willard Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects Br J Clin Pharmacol 29 1990 239 243
14. R.K. Miller, P.J. Wier, D. Maulik, and P.A. di Sant'Agnese Human placenta in vitro: characterization during 12 h of dual perfusion Contrib Gynecol Obstet 13 1985 77 84
15. T. Nanovskaya, S. Deshmukh, M. Brooks, and M.S. Ahmed Transplacental transfer and metabolism of buprenorphine J Pharmacol Exp Ther 300 2002 26 33
16. F. Ushigome, N. Koyabu, and S. Satoh Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles Pharm Res 20 2003 38 44
17. S.J. Hemauer, S.L. Patrikeeva, T.N. Nanovskaya, G.D. Hankins, and M.S. Ahmed Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles Biochem Pharmacol 78 2009 1272 1278
18. T.N. Nanovskaya, S. Patrikeeva, Y. Zhan, G.D. Hankins, and M.S. Ahmed Transplacental transfer of oseltamivir carboxylate J Matern Fetal Neonatal Med 25 2012 2312 2315
19. J.E. Karlsson, C. Heddle, and A. Rozkov High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-Epstein-Barr virus nuclear antigen cells Drug Metab Dispos 38 2010 705 714
20. M. Yamazaki, K. Kobayashi, and Y. Sugiyama Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats Biopharm Drug Dispos 17 1996 645 659
21. S. Matsushima, K. Maeda, and C. Kondo Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein J Pharmacol Exp Ther 314 2005 1059 1067
22. R. Elsby, V. Smith, and L. Fox Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions Xenobiotica 41 2011 764 783
23. K. Vähäkangas, and P. Myllynen Drug transporters in the human blood-placental barrier Br J Pharmacol 158 2009 665 678
24. M.A. Serrano, R.I. Macias, and O. Briz Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory bunction of the placenta Placenta 28 2007 107 117
25. C. Chen, R.J. Mireles, and S.D. Campbell Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab Dispos 33 2005 537 546
26. M. Hirano, K. Maeda, H. Hayashi, H. Kusuhara, and Y. Sugiyama Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin J Pharmacol Exp Ther 314 2005 876 882 Development